{"id":"https://openalex.org/W2011556296","doi":"https://doi.org/10.1097/coc.0b013e3181d2ed67","title":"A Pilot Study of Bevacizumab and Interferon-\u03b12b in Ocular Melanoma","display_name":"A Pilot Study of Bevacizumab and Interferon-\u03b12b in Ocular Melanoma","publication_year":2010,"publication_date":"2010-05-11","ids":{"openalex":"https://openalex.org/W2011556296","doi":"https://doi.org/10.1097/coc.0b013e3181d2ed67","mag":"2011556296","pmid":"https://pubmed.ncbi.nlm.nih.gov/20458209","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4294796"},"language":"en","primary_location":{"id":"doi:10.1097/coc.0b013e3181d2ed67","doi":"https://doi.org/10.1097/coc.0b013e3181d2ed67","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coc.0b013e3181d2ed67","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4294796","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074355506","display_name":"Kristan D. Guenterberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kristan D. Guenterberg","raw_affiliation_strings":["Division of Surgical Oncology, The Ohio State University, Columbus, Ohio 43210, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Surgical Oncology, The Ohio State University, Columbus, Ohio 43210, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044698569","display_name":"Valerie Patrice Grignol","orcid":"https://orcid.org/0000-0002-8574-0715","observed_orcids":["https://orcid.org/0000-0002-8574-0715"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Valerie P. Grignol","raw_affiliation_strings":["Division of Surgical Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Surgical Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016642564","display_name":"Kiran Relekar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kiran V. Relekar","raw_affiliation_strings":["Division of Surgical Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Surgical Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077210752","display_name":"Kimberly A. Varker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kimberly A. Varker","raw_affiliation_strings":["Division of Surgical Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Surgical Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110476583","display_name":"Helen X. Chen","orcid":"https://orcid.org/0000-0001-9959-8417","observed_orcids":["https://orcid.org/0000-0001-9959-8417"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen X. Chen","raw_affiliation_strings":["National Cancer Institute, CTEP, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Institute, CTEP, Bethesda, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045110376","display_name":"Kari Lynn Kendra","orcid":"https://orcid.org/0000-0001-5936-6689","observed_orcids":["https://orcid.org/0000-0001-5936-6689"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kari L. Kendra","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063621818","display_name":"Thomas E. Olencki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas E. Olencki","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060897770","display_name":"William Edgar Carson","orcid":"https://orcid.org/0000-0001-7024-7533","observed_orcids":["https://orcid.org/0000-0001-7024-7533"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William E. Carson","raw_affiliation_strings":["Division of Surgical Oncology, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Surgical Oncology, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5016642564","https://openalex.org/A5044698569","https://openalex.org/A5060897770","https://openalex.org/A5074355506","https://openalex.org/A5077210752"],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":null,"apc_paid":null,"fwci":0.6929,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.73966452,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"34","issue":"1","first_page":"87","last_page":"91"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11328","display_name":"Ocular Oncology and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11328","display_name":"Ocular Oncology and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9539999961853027},{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.9710000157356262},{"id":"https://openalex.org/keywords/ocular-melanoma","display_name":"ocular melanoma","score":0.8690000176429749},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6510000228881836},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor-inhibition","display_name":"vascular endothelial growth factor inhibition","score":0.8700000047683716},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.6330000162124634},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6439999938011169},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.578000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9779860973358154},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8335700631141663},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6182076930999756},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5845175981521606},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5569392442703247},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5021188259124756},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.480365127325058},{"id":"https://openalex.org/C2779561371","wikidata":"https://www.wikidata.org/wiki/Q570197","display_name":"Proteinuria","level":3,"score":0.46152156591415405},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.4252975285053253},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4234035611152649},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.41357290744781494},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4129626750946045},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3699679374694824},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.0},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005134","descriptor_name":"Eye Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005134","descriptor_name":"Eye Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1097/coc.0b013e3181d2ed67","doi":"https://doi.org/10.1097/coc.0b013e3181d2ed67","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coc.0b013e3181d2ed67","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:20458209","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20458209","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of clinical oncology","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:europepmc.org:3261368","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4294796","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4294796","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4294796","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Am J Clin Oncol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3261368","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4294796","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1545320450","display_name":"Innate Immunity: Elucidation and Modulation for Cancer Therapy","funder_award_id":"P01CA095426","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2513009810","display_name":null,"funder_award_id":"N01 CM062207","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G258994785","display_name":"Phase I Trials of Anti-Cancer Agents","funder_award_id":"U01CA076576","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3131659191","display_name":"A program of immune-based treatments for cancer","funder_award_id":"K24CA093670","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3250576571","display_name":"Phase 2 Study of Anti Vegf Antibody in Melanoma","funder_award_id":"R21CA093071","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3506765365","display_name":"Oncology Training Grant","funder_award_id":"T32CA009338","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4506414524","display_name":"Tumor Immunology","funder_award_id":"T32CA090223","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7306595691","display_name":null,"funder_award_id":"CA093071","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8144716091","display_name":"Early Therapeutics Development with Phase II Emphasis","funder_award_id":"n01cm62207-12-0-1","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000887552","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016058","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":40,"referenced_works":["https://openalex.org/W119110597","https://openalex.org/W1545177819","https://openalex.org/W1585398965","https://openalex.org/W1605890004","https://openalex.org/W1969624479","https://openalex.org/W1969787193","https://openalex.org/W1971366285","https://openalex.org/W1972572379","https://openalex.org/W1972952928","https://openalex.org/W1994536517","https://openalex.org/W2000292756","https://openalex.org/W2003446651","https://openalex.org/W2028825060","https://openalex.org/W2033597946","https://openalex.org/W2043410848","https://openalex.org/W2046507292","https://openalex.org/W2046598720","https://openalex.org/W2052066839","https://openalex.org/W2056723407","https://openalex.org/W2065660815","https://openalex.org/W2072507821","https://openalex.org/W2073115805","https://openalex.org/W2078625851","https://openalex.org/W2095038799","https://openalex.org/W2097875955","https://openalex.org/W2103772491","https://openalex.org/W2108527315","https://openalex.org/W2114159573","https://openalex.org/W2115369775","https://openalex.org/W2123033514","https://openalex.org/W2126275851","https://openalex.org/W2137191111","https://openalex.org/W2141213947","https://openalex.org/W2145835533","https://openalex.org/W2157769714","https://openalex.org/W2165636771","https://openalex.org/W2171444350","https://openalex.org/W2233380081","https://openalex.org/W2340893063","https://openalex.org/W4252851641"],"related_works":["https://openalex.org/W1985126174","https://openalex.org/W2035337464","https://openalex.org/W2245985650","https://openalex.org/W1990352059","https://openalex.org/W2280667057","https://openalex.org/W4224854582","https://openalex.org/W4249382411","https://openalex.org/W1505735082","https://openalex.org/W2095479209","https://openalex.org/W2065660815"],"abstract_inverted_index":{"OBJECTIVES:":[0],"We":[1],"hypothesized":[2],"that":[3,10],"administration":[4],"of":[5,24,68,80,104,170,185,205,225],"bevacizumab,":[6],"a":[7,66,75,101,157],"monoclonal":[8],"antibody":[9],"neutralizes":[11],"vascular":[12],"endothelial":[13],"growth":[14,27],"factor,":[15,28],"in":[16,33,167,176,214,228,232],"combination":[17,229],"with":[18,35,41,100,156,230],"high-dose":[19,226],"interferon-alpha2b":[20],"(IFN-\u03b12b),":[21],"an":[22],"inhibitor":[23],"basic":[25],"fibroblast":[26],"would":[29],"have":[30],"clinical":[31,76,219],"activity":[32,220],"patients":[34,93,182,194],"metastatic":[36,42],"ocular":[37,43],"melanoma.":[38],"METHODS:":[39],"Patients":[40,73],"melanoma":[44],"received":[45],"bevacizumab":[46,231],"(15":[47],"mg/kg":[48],"intravenously":[49],"every":[50],"2":[51,62,98,144,181],"weeks)":[52],"plus":[53],"IFN-\u03b12b":[54,210,227],"(5":[55],"MU/m":[56,70],"subcutaneously":[57,71],"3":[58,122,127,133,138,149],"times":[59],"weekly":[60],"for":[61],"weeks":[63,204],"followed":[64],"by":[65,172],"dose":[67,161],"10":[69],"thereafter).":[72],"exhibiting":[74],"response":[77],"or":[78,160],"stabilization":[79,184],"disease":[81,85,186],"were":[82,94,119,211],"treated":[83,95],"until":[84],"progression.":[86],"RESULTS:":[87],"In":[88],"this":[89,215,233],"pilot":[90],"study,":[91],"5":[92],"(3":[96],"men,":[97],"women)":[99],"mean":[102],"age":[103],"63.8":[105],"years":[106],"(range,":[107],"53-71":[108],"years).":[109],"Overall,":[110],"the":[111],"regimen":[112],"was":[113,221],"well-tolerated.":[114],"The":[115],"following":[116],"adverse":[117,153],"events":[118,154],"noted:":[120],"grade":[121,126,132,137,141,148],"dyspnea":[123],"(2":[124],"patients),":[125],"and":[128,143,147,180,189,198,202,209,218],"4":[129],"fatigue":[130],"(2),":[131,146],"muscle":[134],"weakness":[135],"(1),":[136,140],"anorexia":[139],"1":[142],"proteinuria":[145],"diarrhea":[150],"(1).":[151],"All":[152],"resolved":[155],"treatment":[158],"holiday":[159],"reduction.":[162],"One":[163],"patient":[164,216],"had":[165,183],"reduction":[166],"tumor":[168],"burden":[169],"23%":[171],"Response":[173],"Evaluation":[174],"Criteria":[175],"Solid":[177],"Tumors":[178],"criteria":[179],"lasting":[187],"28":[188],"36":[190],"weeks,":[191],"respectively.":[192],"Two":[193],"failed":[195],"to":[196],"respond":[197],"progressed":[199],"after":[200],"6":[201],"7":[203],"therapy.":[206],"CONCLUSION:":[207],"Bevacizumab":[208],"well":[212],"tolerated":[213],"population,":[217],"observed.":[222],"Further":[223],"study":[224],"setting":[234],"is":[235],"warranted.":[236]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2016-06-24T00:00:00"}